177 related articles for article (PubMed ID: 24338995)
1. Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
Kwak M; Jung SH
Stat Med; 2014 May; 33(12):2004-16. PubMed ID: 24338995
[TBL] [Abstract][Full Text] [Related]
2. Optimal two-stage log-rank test for randomized phase II clinical trials.
Kwak M; Jung SH
J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043
[TBL] [Abstract][Full Text] [Related]
3. Optimal two-stage designs for phase II clinical trials.
Simon R
Control Clin Trials; 1989 Mar; 10(1):1-10. PubMed ID: 2702835
[TBL] [Abstract][Full Text] [Related]
4. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
5. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
6. Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes.
Wason JM; Mander AP
J Biopharm Stat; 2012; 22(4):836-52. PubMed ID: 22651118
[TBL] [Abstract][Full Text] [Related]
7. Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
[TBL] [Abstract][Full Text] [Related]
8. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
9. Two-stage phase II survival trial design.
Wu J; Chen L; Wei J; Weiss H; Chauhan A
Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
[TBL] [Abstract][Full Text] [Related]
10. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
11. An optimal three-stage design for phase II clinical trials.
Ensign LG; Gehan EA; Kamen DS; Thall PF
Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
[TBL] [Abstract][Full Text] [Related]
12. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
[TBL] [Abstract][Full Text] [Related]
13. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
14. Optimal two-stage designs for single arm phase II cancer trials.
Shuster J
J Biopharm Stat; 2002 Feb; 12(1):39-51. PubMed ID: 12146719
[TBL] [Abstract][Full Text] [Related]
15. Two-stage optimal designs based on exact variance for a single-arm trial with survival endpoints.
Shan G
J Biopharm Stat; 2020 Sep; 30(5):797-805. PubMed ID: 32129130
[TBL] [Abstract][Full Text] [Related]
16. Two-stage k-sample designs for the ordered alternative problem.
Shan G; Hutson AD; Wilding GE
Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
[TBL] [Abstract][Full Text] [Related]
17. An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
Wunder C; Kopp-Schneider A; Edler L
J Biopharm Stat; 2012; 22(2):294-311. PubMed ID: 22251175
[TBL] [Abstract][Full Text] [Related]
18. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.
Mander AP; Wason JM; Sweeting MJ; Thompson SG
Pharm Stat; 2012; 11(2):91-6. PubMed ID: 22232071
[TBL] [Abstract][Full Text] [Related]
19. One-sample proportion testing procedures for hypothesis of inequality.
Zhong W; Zhong B
J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
[TBL] [Abstract][Full Text] [Related]
20. Two-stage phase II oncology designs using short-term endpoints for early stopping.
Kunz CU; Wason JM; Kieser M
Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
